Compare Crispr Therapeutics AG (CRSP) vs Deckers Outdoor Corp (DECK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Deckers Outdoor Corp — how do they compare? Crispr Therapeutics AG trades at $50.71 (market cap $4.97B), while Deckers Outdoor Corp trades at $106.98 (market cap $14.80B). The key difference: Deckers Outdoor Corp is far larger — about 3× Crispr Therapeutics AG's market cap, and Deckers Outdoor Corp is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | DECK | |
|---|---|---|
Market Cap | $4.97B | $14.80B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $123.91 |
52-Week Low | $44.34 | $79.54 |
Enterprise Value | $3.32B | $13.27B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
DECK trades at $107.80, up 1.71% for the day, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.96 exceeding the $0.83 estimate. Revenue grew to $4.99B in 2025, and net income reached $966M. Analyst consensus price target is $122.44, suggesting potential upside. Recent news highlights robust brand momentum for UGG and HOKA, with international sales growth offsetting domestic stagnation.
Outlook remains positive driven by earnings growth and strong cash flow, but risks include reliance on key brands and competitive pressures. The stock offers a reasonable valuation with a P/E of 15.36 and high profitability metrics, though technical indicators show some overbought conditions near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →
